Matejíková J, Kucharská J, Pancza D, Ravingerová T
Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Physiol Res. 2008;57 Suppl 2:S55-S60. doi: 10.33549/physiolres.931552. Epub 2008 Mar 28.
Contrary to clinical trials, experimental studies revealed that diabetes mellitus (DM) may initiate, besides increased myocardial vulnerability to ischemia-reperfusion injury (I/R) and pro/antioxidant dysbalance, development of adaptation leading to an enhanced tolerance to I/R. The aims were to characterize 1) susceptibility to ischemia-induced ventricular arrhythmias in the diabetic rat heart 2) its response to antioxidant N-acetylcysteine (NAC) and a NOS inhibitor L-NAME, and 3) the effect of DM on endogenous antioxidant systems. Seven days after streptozotocin injection (65 mg/kg, i.p.), Langendorff-perfused control (C) and DM hearts were subjected to 30-min occlusion of the LAD coronary artery with or without prior 15-min treatment with L-NAME (100 microM) or NAC (4 mM). Total number of ventricular premature beats (VPB), as well the total duration of ventricular tachycardia (VT) were reduced in the DM group (from 533+/-58 and 37.9+/-10.2 s to 224.3+/-52.6 and 19+/-13.5 s; P<0.05). In contrast to the antiarrhythmic effects of L-NAME and NAC in controls group (VPB 290+/-56 and 74+/-36, respectively; P<0.01 vs. control hearts), application of both drugs in the diabetics did not modify arrhythmogenesis (L-NAME: VPB 345+/-136, VT 25+/-13 s; NAC: VPB 207+/-50, VT 12+/-3.9 s; P>0.05 vs non-treated diabetic hearts). Diabetic state was associated with significantly elevated levels of CoQ10 and CoQ9 (19.6+/-0.8 and 217.3+/-9.5 vs. 17.4+/- 0.5 and 185.0+/-5.0 nmol/g, respectively, in controls; P<0.05), as well as alpha-tocopherol (38.6+/-0.7 vs. 31.5+/-2.1 nmol/g in controls; P<0.01) in the myocardial tissue. It is concluded that early period of DM is associated with enhanced resistance to ischemia-induced arrhythmias. Diabetes mellitus might induce adaptive processes in the myocardium leading to lower susceptibility to antioxidant and L-NAME treatment.
与临床试验相反,实验研究表明,糖尿病(DM)除了会增加心肌对缺血再灌注损伤(I/R)的易感性以及导致促氧化剂/抗氧化剂失衡外,还可能引发适应性变化,从而增强对I/R的耐受性。本研究旨在:1) 确定糖尿病大鼠心脏对缺血诱导的室性心律失常的易感性;2) 观察其对抗氧化剂N-乙酰半胱氨酸(NAC)和一氧化氮合酶抑制剂L-NAME的反应;3) 研究糖尿病对内源性抗氧化系统的影响。链脲佐菌素腹腔注射(65mg/kg)7天后,对采用Langendorff灌注的对照组(C)和糖尿病组心脏进行实验,在冠状动脉左前降支(LAD)闭塞30分钟前,分别给予15分钟的L-NAME(100μM)或NAC(4mM)预处理,或不进行预处理。糖尿病组室性早搏(VPB)总数以及室性心动过速(VT)总时长均减少(分别从533±58和37.9±10.2秒降至224.3±52.6和19±13.5秒;P<0.05)。与L-NAME和NAC在对照组中的抗心律失常作用相反(对照组VPB分别为290±56和74±36;与对照心脏相比P<0.01),在糖尿病组中应用这两种药物并未改变心律失常的发生(L-NAME:VPB 345±136,VT 25±13秒;NAC:VPB 207±50,VT 12±3.9秒;与未治疗的糖尿病心脏相比P>0.05)。糖尿病状态与心肌组织中辅酶Q10和辅酶Q9水平显著升高有关(对照组分别为19.6±0.8和217.3±9.5,糖尿病组分别为17.4±0.5和185.0±5.0nmol/g;P<0.05),同时也与α-生育酚水平升高有关(对照组为31.5±2.1nmol/g,糖尿病组为38.6±0.7nmol/g;P<0.01)。研究得出结论,糖尿病早期与对缺血诱导的心律失常的抵抗力增强有关。糖尿病可能会在心肌中诱导适应性过程,导致对抗氧化剂和L-NAME治疗的敏感性降低。